EarningsQ4 2025 Earnings Report
MX:BEAM Q4 2025 EPS Results
Actual EPS$39.55
Consensus EPS-$17.15
Beat/MissBeat by +$56.70
One Year Ago EPS-$18.50
MX:BEAM Q4 2025 Revenue Results
Actual Revenue$1.94B
Expected Revenue$198.09M
Beat/MissBeat by +$1.74B
YoY Revenue Growth+279.52%
Earnings Announcement Details
QuarterQ4 2025
Date02/24/2026
TimeBefore Open
Conference CallTuesday, February 24, 2026
MX:BEAM Upcoming Earnings
Beam Therapeutics's next earnings date is estimated for November 9, 2026, based on past reporting schedules.
Q4 2025 Earnings Call Audio
MX:BEAM Q4 2025 Earnings Call
0:00 / 0:00
Q4 2025 Earnings Slide Deck
No slide deck is available for this earnings event.
Q4 2025 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented substantial positive momentum: a new liver-targeted PKU program with strong preclinical efficacy, constructive FDA engagement around an umbrella platform approach, demonstrated LNP and manufacturing capabilities, and a major non-dilutive financing that extends runway into mid-2029. Key risks highlighted include regulatory ambiguity for novel individualized pathways, the large diversity of PAH variants (necessitating personalized approaches), limited public detail on bystander/off-target profiles, and conditional milestone-based financing. On balance, the updates emphasize progress, resources, and clear near-term milestones while acknowledging technical and regulatory uncertainties that are typical for platform-based gene editing development.Company Guidance
New PKU Program (BEAM-304) Initiated and Rapidly Advanced
Beam announced BEAM-304, a liver-targeted base editing program for phenylketonuria (PKU). The company identified two development candidates (including R408W) that together could treat nearly half (~50%) of PKU patients in the U.S. Initial IND-enabling work was advanced in under 2 years with an IND planned to be filed in 2026.
Strong Preclinical Efficacy for BEAM-304
Preclinical data in mouse models showed rapid and robust plasma phenylalanine (Phe) reductions after a single dose (0.3 mg/kg). In animal studies Phe was reduced below the therapeutic threshold by day 7 (and in a separate humanized model normalized by 48 hours), with a predictable dose–response between on-target liver editing and Phe reduction.
Regulatory Engagement and Innovative Trial Design Support
Beam reported productive pre-IND interactions with FDA and substantive discussions supporting a platform/umbrella approach (multiple mutation-specific editors in a single IND) and the ability to add new variants via rapid IND amendments using in vitro data, potentially enabling faster addition of mutation-specific editors.
LNP Delivery Expertise and Manufacturing Capability
Beam emphasized internally developed LNP delivery and optimization expertise, including proprietary ionizable lipids and internal GMP manufacturing capacity in North Carolina, enabling outpatient IV dosing, titratability and redoseability for liver-directed programs.
Strategic Non-Dilutive Financing to Strengthen Balance Sheet
Beam entered a long-term financing facility with Sixth Street providing up to $500 million: $100M funded at close, up to $300M tied to milestones, and an additional $100M subject to agreement. Repayment of principal is due in early 2033.
Healthy Cash Balance and Extended Runway
Beam ended 2025 with $1.25 billion in cash, cash equivalents and marketable securities. With the anticipated minimum draw of $200M from the Sixth Street facility, management expects runway to extend into mid-2029 to support pipeline execution and anticipated commercialization activities.
Clear Development Milestones and Pipeline Momentum
Near-term expectations include BEAM-302 pivotal planning update (alpha-1 antitrypsin deficiency) this quarter, potential risto-cel BLA submission as early as year-end, IND filing for BEAM-304 in 2026, initial BEAM-301 data in GSDIa, completion of BEAM-103 healthy volunteer study, and continued in vivo HSC editing work.
Clinical Need and Market Opportunity Quantified
PKU: ~20,000 individuals in the U.S.; regulatory precedent accepts blood Phe reduction as an endpoint for full approval in U.S./EU. Clinical data cited: ~30% of R408W patients had lifetime average Phe above recommended maximum; only ~25% of adult PKU patients maintain Phe <360 µM; enzyme replacement therapy reaches target in ~60% of patients after 1–2 years.
MX:BEAM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed